Note 5. Other Financial Information

Collaboration Receivables

Collaboration receivables of $17,544 as of September 30, 2011 includes $12,928 due to the Company from GSK for manufacturing costs incurred to produce pre-launch commercial product which is expected to be sold within the next year. Collaboration receivables also include $3,483 in unbilled receivables from GSK in connection with the Company's cost-sharing agreements and other unbilled receivables. Collaboration receivables of $18,856 as of December 31, 2010 includes $13,165 due to the Company from GSK for manufacturing costs incurred to produce pre-launch commercial product which is expected to be sold within the next year, $5,166 in unbilled receivables from GSK in connection with the Company's cost sharing agreements and other unbilled receivables.

Collaboration receivables, non-current of $25,276 and $29,225 as of September 30, 2011 and December 31, 2010, respectively, relate to the amount due to the Company from GSK for manufacturing costs incurred to produce pre-launch commercial product which is not expected to be sold within the next year.

Inventory

Inventories consist of the following:


	September 30, 2011				December 31, 2010
	Current		Non-current		Current		Non-current

Raw materials	$	14,694	$	11,969	$	12,641	$	—
Work-in-process		16,854		69,396		23,426		—
Finished goods		8,695		3,704		7,024		—

Total	$	40,243	$	85,069	$	43,091	$	—

Inventory that is not expected to be sold until more than 12 months from the balance sheet date is classified as non-current.

BENLYSTA-related inventories that were either purchased or manufactured prior to the date the Company began capitalizing BENLYSTA inventory (November 2010) were $101,639 and $112,822 as of September 30, 2011 and December 31, 2010, respectively. These inventories have a carrying value of zero, as the costs to purchase or produce this inventory were expensed as research and development expense in the period manufactured, and accordingly are not reflected in the inventory balances shown above. These inventories could be used in clinical trials, sold in the U.S. as commercial product or sold to GSK at cost for the ROW sale of BENLYSTA.

As of September 30, 2011, current inventory includes an aggregate of $3,365 of raw materials and work in process relating to anticipated future orders for raxibacumab beyond that which is required to fulfill the second order from the USG. The Company currently expects to recover the cost of this inventory through future sales of raxibacumab. If the Company does not receive additional orders for raxibacumab, it would need to record a charge to cost of sales for this amount of inventory.

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets of $13,958 and $5,569 as of September 30, 2011 and December 31, 2010, respectively, consisted primarily of deposits, deferred financing fees and insurance payments made in advance.

Collaboration Payable

Collaboration payable of $33,552 as of September 30, 2011, represents cost reimbursements due to GSK in connection with the Company's cost sharing agreements. Collaboration payable of $12,984 as of December 31, 2010 represents cost reimbursements due to GSK and Novartis in connection with the Company's cost sharing agreements.